Usual Adult Dose for Migraine Prophylaxis

Initial dose: 240 mg subcutaneously once
Maintenance dose: 120 mg subcutaneously monthly

Comments:

• The first dose is a loading dose consisting of 2 consecutive subcutaneous injections of 120 mg each.
• If a dose is missed, administer as soon as possible. Thereafter, dose can be scheduled from the date of the last dose.

Usual Adult Dose for Cluster Headache

Initial dose: 300 mg subcutaneously at the onset of the cluster period
Maintenance dose: 300 mg subcutaneously once a month until the end of the cluster period

Comments:

• Each dose is administered as 3 consecutive subcutaneous injections of 100 mg each.
• This drug is to be injected once a month for the length of a cluster period which may extend from several weeks to months.
• If a dose is missed, administer as soon as possible. Thereafter, dose can be scheduled monthly from the date of the last dose.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

CONTRAINDICATIONS:

• Serious hypersensitivity reaction to this drug or any of the excipients

Dialysis

Data not available

Other Comments

Administration advice:

• For subcutaneous administration use only
• Administer subcutaneously into abdomen, thigh, or back of upper arm or buttocks
• Do not inject into areas that are tender, bruised, red, or indurated

• Not in use: Refrigerate 36F to 46F (2C to 8C); Protect from light
• In-use: Once removed from refrigerator, may keep at temperatures below 86F (30C) for up to 7 days; once removed from the refrigerator, do not put back in the refrigerator
• Do not shake; do not freeze; do not expose to extreme heat or direct sunlight

• Remove from refrigerator and allow to sit at room temperature from 30 minutes prior to use; do not warm using a heat source such as hot water or microwave
• Consult manufacturer's product information for additional information and illustrations

• This drug is intended for self-administration; prior to use, patients should be provided with proper training.

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Patients and/or caregivers should be instructed to contact their health care provider if they have questions on administration.
• Patients should be informed that hypersensitivity reactions may occur, and they should notify their healthcare provider if they develop.

Frequently asked questions

• What are the new drugs for the treatment of migraines?
• Emgality vs Aimovig - how do they compare?
• Ubrelvy vs Emgality: How do they compare for migraines?
• What is the cost of the migraine drug Ajovy?
• What type of drug is Ajovy?
• What type of drug is Emgality?